Tocilizumab zur Behandlung einer Patientin mit schwerer anteriorer Uveitis und juveniler idiopathischer Arthritis

T. Lutz; A. Helling-Bakki; A. Knoll; J. Grulich-Henn; F. Mackensen

doi:10.1055/s-0037-1617731

Arthritis und Rheuma, Inhaltsverzeichnis

Arthritis und Rheuma 2016; 36(06): 411-413
DOI: 10.1055/s-0037-1617731

Kinderrheumatologie/Kasuistik

Schattauer GmbH

Tocilizumab zur Behandlung einer Patientin mit schwerer anteriorer Uveitis und juveniler idiopathischer Arthritis

T. Lutz

¹Zentrum für Kinder- und Jugendmedizin, Klinik 1, Universitätsklinikum Heidelberg, Heidelberg

²Interdisziplinäres Uveitiszentrum, Universitätsaugenklinik, Universitätsklinikum Heidelberg, Heidelberg

,

A. Helling-Bakki

¹Zentrum für Kinder- und Jugendmedizin, Klinik 1, Universitätsklinikum Heidelberg, Heidelberg

,

A. Knoll

²Interdisziplinäres Uveitiszentrum, Universitätsaugenklinik, Universitätsklinikum Heidelberg, Heidelberg

,

J. Grulich-Henn

¹Zentrum für Kinder- und Jugendmedizin, Klinik 1, Universitätsklinikum Heidelberg, Heidelberg

,

F. Mackensen

²Interdisziplinäres Uveitiszentrum, Universitätsaugenklinik, Universitätsklinikum Heidelberg, Heidelberg

Literatur
1 Yoshimura KHSonoda, Ohguro N, Ohsugi Y. et al. Involvement of Th17 cells and the effect of antiIL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009; 48 (04) 347-354 [Epub 2009 Jan 22].
2 Muselier A, Bielefeld P, Bidot S. et al. Efficacy of Tocilizumab in Two Patients with anti-TNF-alpha Refractory Uveitis. Ocular Immunology & Inflammation 2011; 19 (05) 382-383.
3 Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?. J Rheumatol 2012; 39 (06) 1294-1295.
4 Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 2014; 252 (01) 163-164 [Epub 2013 Sep 24].
5 Calvo-Río V, de la DHera, Beltrán-Catalán E. et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 2014; 32 (4 Suppl 84) S54-S57 [Epub 2014 Jul 8].
6 Mesquida M, Molins B, Llorenç V. et al. Current and future treatments for Behçet’s uveitis: road to remission. Int Ophthalmol 2014; 34 (02) 365-381 [Epub 2013 Jun 1].
7 Papo M, Bielefeld P, Vallet H. et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 2014; 32 (4 Suppl 84): S75-S79 [Epub 2014 Sep 30].
8 Mackensen F, Lutz T. Therapy for childhood uveitis: biologics: too often - too late?. Ophthalmologe 2011; 108 (03) 213-221.
9 Jabs DA, 1 Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140 (03) 509-516.
10 Heiligenhaus A, Heinz C, Edelsten C. et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013; 21 (03) 180-191.
11 Heiligenhaus A, Horneff G, Greiner K. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007; 46 (06) 1015-1019 [Epub 2007 Apr 2].
12 Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210 [Epub 2010 Feb 18].
13 Simonini G, Taddio A, Cattalini M. et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pedisatr Rheumatol Online J 2013; 11: 16.
14 Tappeiner C, Miserocchi E, Bodaghi B. et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42 (04) 706-711 [Epub 2015 Feb 1].
15 Heiligenhaus A, Miserocchi E, Heinz C. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50 (08) 1390-1394 [Epub 2011 Mar 4].
16 Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford) 2015; 54 (07) 1170-1176 [Epub 2014 Dec 10].
17 Little JA, Sen ES, Strike H. et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. J Rheumatol 2014; 41 (01) 136-139 [Epub 2013 Oct 1].
18 Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS 2008; 12 (06) 611-613 [Epub 2008 Oct 19].
19 Tappeiner C, Mesquida M, Adán A. et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016 Sep 15. pii: jrheum.160231. [Epub ahead of print].